← Leaderboards
Jamey P Weichert
University Of Wisconsin Madison
$8,781,489
Attributed
$11,517,478
Total exposure
17
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,388,291 · 19
By mechanism
P01$15,529,868 · 6
U01$3,990,219 · 1
S10$1,947,878 · 7
P30$1,361,754 · 3
R01$1,194,822 · 1
R21$363,750 · 1
Top collaborators
- Zachary Scott Morris18 shared
- Lance T Hall4 shared
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Paul M Sondel$16,210,986
- Paul M Harari$4,871,007
- Tomy Varghese$7,667,600
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorRadiationImageResponseMalignant NeoplasmsRadiation TherapyModalitySafetyProgramsImmunotherapyServicesIn VivoImmunoregulationMolecular TargetRadionuclide TherapyLeadershipAwardDoseCellsEnsureTumor MicroenvironmentDosimetryPre-ClinicalResearch Personnel
Grant awards (58)
Small Animal Imaging and Radiotherapy Facility$39,393
P30 · FY2025 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,361,658
P01 · FY2024 · CA · contact PI
UW PET/CT Acquisition$576,756
S10 · FY2024 · OD · contact PI
Novel Molecular Targeted Radionuclide Therapies for Dosimetry-Guided Immunomodulation$330,189
P01 · FY2024 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$191,077
P01 · FY2024 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$72,263
P01 · FY2024 · CA · contact PI
Administrative-Core-001$72,263
P01 · FY2024 · CA · contact PI
Administrative-Core-001$70,096
P01 · FY2024 · CA · contact PI
Small Animal Imaging and Radiotherapy Facility$39,393
P30 · FY2024 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,452,679
P01 · FY2023 · CA · contact PI
Novel Molecular Targeted Radionuclide Therapies for Dosimetry-Guided Immunomodulation$351,030
P01 · FY2023 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$203,129
P01 · FY2023 · CA · contact PI
Administrative-Core-001$74,545
P01 · FY2023 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$74,545
P01 · FY2023 · CA · contact PI
Small Animal Imaging and Radiotherapy Facility$39,393
P30 · FY2023 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,453,778
P01 · FY2022 · CA · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2022 · CA
Novel Molecular Targeted Radionuclide Therapies for Dosimetry-Guided Immunomodulation$351,029
P01 · FY2022 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$203,129
P01 · FY2022 · CA · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$165,219
U01 · FY2022 · CA
Small Animal Imaging Facility Shared Resource$83,651
P30 · FY2022 · CA · contact PI
Administrative-Core-001$70,033
P01 · FY2022 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$70,033
P01 · FY2022 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,508,454
P01 · FY2021 · CA · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2021 · CA
Novel Molecular Targeted Radionuclide Therapies for Dosimetry-Guided Immunomodulation$358,098
P01 · FY2021 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$207,220
P01 · FY2021 · CA · contact PI
Small Animal Imaging Facility Shared Resource$102,107
P30 · FY2021 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$2,490,943
P01 · FY2020 · CA · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2020 · CA
UW SPECT/CT Acquisition$598,202
S10 · FY2020 · OD · contact PI
Novel Molecular Targeted Radionuclide Therapies for Dosimetry-Guided Immunomodulation$357,068
P01 · FY2020 · CA · contact PI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response$206,609
P01 · FY2020 · CA · contact PI
Small Animal Imaging Facility Shared Resource$102,182
P30 · FY2020 · CA · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2019 · CA
Small Animal Imaging Facility Shared Resource$102,186
P30 · FY2019 · CA · contact PI
Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies$765,000
U01 · FY2018 · CA
Small Animal Imaging Facility Shared Resource$97,040
P30 · FY2018 · CA · contact PI
Small Animal Imaging Facility Shared Resource$10,871
P30 · FY2018 · CA · contact PI
Small Animal Imaging Facility Shared Resource$5,924
P30 · FY2018 · CA · contact PI
Small Animal Imaging Facility Shared Resource$3,293
P30 · FY2018 · CA · contact PI
Small Animal Imaging Facility Shared Resource$673
P30 · FY2018 · CA · contact PI
PET/CT Imaging of Malignant Brain Tumors with 124I-NM404$296,414
R01 · FY2014 · CA · contact PI
PET/CT Imaging of Malignant Brain Tumors with 124I-NM404$287,246
R01 · FY2013 · CA · contact PI
PET/CT Imaging of Malignant Brain Tumors with 124I-NM404$305,581
R01 · FY2012 · CA · contact PI
PET/CT Imaging of Malignant Brain Tumors with 124I-NM404$305,581
R01 · FY2011 · CA · contact PI
Small Animal Imaging$144,158
P30 · FY2011 · CA · contact PI
Small Animal Imaging$152,289
P30 · FY2010 · CA · contact PI
Small Animal Imaging$144,563
P30 · FY2009 · CA · contact PI
Small Animal Imaging$142,922
P30 · FY2008 · CA · contact PI
Small Animal Imaging$151,716
P30 · FY2007 · CA · contact PI
ImTek MicroCAT II MicroCT Scanner$386,460
S10 · FY2005 · RR
IMTEK MICROCAT II MICROCT SCANNER: CANCER$266,657
S10 · FY2005 · RR
IMTEK MICROCAT II MICROCT SCANNER: BREAST, PANCREATIC, &THYROID CANCER$57,969
S10 · FY2005 · RR
IMTEK MICROCAT II MICROCT SCANNER: CYSTITIS, GENETICS, AND PROSTATE RESEARCH$50,240
S10 · FY2005 · RR
IMTEK MICROCAT II MICROCT SCANNER: AGING$11,594
S10 · FY2005 · RR
Evaluation of NM404 in endogenous breast cancer models$181,875
R21 · FY2004 · CA
Evaluation of NM404 in endogenous breast cancer models$181,875
R21 · FY2003 · CA